Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inpamac Biotech Canada Inc. is pursuing patent protection in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action, which is being processed by 1 distinct examiner. This activity is localized within 1 distinct art unit, suggesting a specialized technical application within the broader pharmaceutical field.
The busiest examiner for Inpamac Biotech Canada Inc. is REGA, KYLE THOMAS, who is currently reviewing the 1 pending office action. This single action constitutes the entire pending workload for the company's portfolio. Consequently, the immediate success of the company's patent filings depends on the specific examination conducted by REGA, KYLE THOMAS.
With only 1 distinct art unit involved, the company faces a consolidated regulatory path. Practitioners can focus on the specific examination styles and precedents relevant to that unit. The presence of 1 distinct examiner means that the company's prosecution strategy does not need to account for varying interpretations across different examiners, focusing instead on the 1 pending office action currently on record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18149913 | CONSTRUCTS, COMPOSITIONS, CELLS AND METHODS FOR INCREASED RECOMBINANT PROTEIN EXPRESSION BY TARGETED INTEGRATION AND AMPLIFICATION | REGA, KYLE THOMAS | 36d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18149913 | CONSTRUCTS, COMPOSITIONS, CELLS AND METHODS FOR INCREASED RECOMBINANT PROTEIN EXPRESSION BY TARGETED INTEGRATION AND AMPLIFICATION | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | 36d overdue | Pending | Jan 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial